Focused On-demand Library for Transcription factor SOX-17

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9H6I2

UPID:
SOX17_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H6I2

BACKGROUND:
The Transcription factor SOX-17 is essential for the regulation of embryonic development, acting as a transcriptional activator in premeiotic germ cells and playing a key role in the definitive gut endoderm development. Its ability to promote CTNNB1 degradation and modulate Wnt signaling pathways is vital for normal physiological processes.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Vesicoureteral reflux 3, a disease affecting the urinary tract, Transcription factor SOX-17 represents a promising target for therapeutic intervention. Exploring the functions of SOX-17 could lead to innovative treatments for urinary tract infections and related renal complications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 212 of 8789